Recent advances in inhibitors of lysine specific demethylase 1 in tumor therapies

Hang Liu,Jie Ding,Zhenhua Liu,Qi Dong,Rui Mi,Zhuan Jiang,Xian Li,Fei Fan,Xuyang Zhang,Longfeng Zhang,Rong Zeng,Zhongmin Zhang
DOI: https://doi.org/10.3760/cma.j.issn.1001-9030.2018.10.066
2018-01-01
Abstract:Lysine specific demethylase 1 (LSD1),a flavin adenine dinucleotidedependent demethylase,specifically catalyzes the demethylation of mono-and di-methylated histone H3 lysine 4 (H3K4) and histone H3 lysine 9 (H3K9) as well as functionally regulates target gene expression.Studies have shown that LSD1 is highly expressed in many malignant tumors and closely related to tumorigenesis,proliferation,invasion and metastasis.Therefore,LSD1 and its inhibitors have recently emerged as sharp research focus.In this review,the authors address the new research findings among the LSD1 inhibitors and tumor therapy.
What problem does this paper attempt to address?